ProPhase Labs Gross Profit Over Time
| PRPH Stock | USD 0.65 0.03 4.41% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ProPhase Labs Performance and ProPhase Labs Correlation. ProPhase |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ProPhase Labs. If investors know ProPhase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (1.53) | Revenue Per Share 0.996 | Quarterly Revenue Growth (0.81) | Return On Assets (0.23) |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ProPhase Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if ProPhase Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ProPhase Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Gross Profit Analysis
Compare ProPhase Labs and related stocks such as LumiraDx, Star Equity Holdings, and Enzo Biochem Gross Profit Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STRR | (3.7 M) | 14.8 M | 13.1 M | 14.1 M | 16.6 M | 17.9 M | 35.8 M | 28.4 M | 18.3 M | 22.1 M | 14 M | 15.2 M | 25.9 M | 11.9 M | 18.7 M |
| ENZ | 5.9 M | 47.1 M | 38.9 M | 41.7 M | 42.8 M | 45.6 M | 48.3 M | 44.3 M | 23.2 M | 23.8 M | 53.6 M | 42 M | 11.6 M | 14.6 M | 13.9 M |
| STIM | 27.6 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | 30.8 M | 40.3 M | 47.3 M | 37.7 M | 43.7 M | 49.7 M | 51.7 M | 45.2 M |
| INBS | 188.7 K | 188.7 K | 188.7 K | 188.7 K | 188.7 K | 188.7 K | 188.7 K | 188.7 K | 188.7 K | 188.7 K | 2 M | 0.0 | 326.7 K | 1.4 M | 862.7 K |
| BDSX | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 16 M | 18.5 M | 23.6 M | 24 M | 24.1 M | 36.1 M | 26.1 M |
| PRPO | 12.5 M | 18.4 M | 15 M | 12.5 M | 9.7 M | (287 K) | (205 K) | 292 K | 225 K | 219 K | 1.1 M | 2.4 M | 2.5 M | 6 M | 7.2 M |
| DRIO | (13.6 M) | (13.6 M) | (13.6 M) | (13.6 M) | (2.2 M) | (855 K) | (561 K) | 1.3 M | 1.8 M | 2.6 M | 2.5 M | 4 M | 9.7 M | 6 M | 6.3 M |
| XGN | (1 M) | (1 M) | (1 M) | 225 K | 4.8 M | 8.4 M | 12.7 M | 12.7 M | 17.1 M | 21.6 M | 25.4 M | 27.7 M | 21.3 M | 29.5 M | 16.8 M |
| SHC | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 357.3 M | 395.4 M | 443.6 M | 518.7 M | 557 M | 577.2 M | 522.3 M |
| BNR | 71.7 M | 71.7 M | 71.7 M | 71.7 M | 71.7 M | 71.7 M | 71.7 M | 71.7 M | 135.1 M | 273.3 M | 313.9 M | 364.1 M | 380 M | 363.2 M | 298.8 M |
| PMD | (200 K) | 14.5 M | 14.3 M | 15.4 M | 15.1 M | 12.7 M | 21.4 M | 19.8 M | 20.6 M | 16.4 M | 4.9 M | 10.3 M | 9.3 M | 8.4 M | 10.9 M |
| SERA | 18 K | 18 K | 18 K | 18 K | 18 K | 18 K | 18 K | 18 K | 18 K | 18 K | 14 K | 45 K | 75 K | 96 K | 54.6 K |
ProPhase Labs and related stocks such as LumiraDx, Star Equity Holdings, and Enzo Biochem Gross Profit description
Gross profit is a required income statement account that reflects total revenue of ProPhase Labs minus its cost of goods sold. It is profit before ProPhase Labs operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.My Equities
My Current Equities and Potential Positions
| ProPhase Labs | PRPH |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Pennsylvania; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.65
Check out ProPhase Labs Performance and ProPhase Labs Correlation. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
ProPhase Labs technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.